JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/75/0.1/17.01.25 | Real-time Bid/Ask 12:17:03 10/06/2024 BST | ||
| 0.005 EUR / 0.015 EUR | +100.00% |
|
| Current month | +25.00% | ||
| 1 month | -28.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 10/06/24 | 0.005 | 0.00% |
| 07/06/24 | 0.005 | 0.00% |
| 06/06/24 | 0.005 | 0.00% |
| 05/06/24 | 0.005 | 0.00% |
| 04/06/24 | 0.005 | 0.00% |
Delayed Quote Börse Stuttgart
Last update June 10, 2024 at 10:54 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JS7PU5 |
| ISIN | DE000JS7PU57 |
| Date issued | 10/02/2023 |
| Strike | 75 $ |
| Maturity | 17/01/2025 (221 Days) |
| Parity | 10 : 1 |
| Emission price | 0.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.87 € |
|---|---|
| Lowest since issue | 0.003 € |
| Spread | 0.01 € |
| Spread % | 66.67% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Warrants
- Warrant